Trial Profile

An Open-label, Multicenter, Phase Ia/Ib Study to Evaluate the Safety, Tolerance and Preliminary Efficacy of IBI319 in Patients With Advanced Malignant Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IBI 319 (Primary)
Indications Haematological malignancies; Solid tumours
Focus Adverse reactions; First in man
Sponsors Innovent Biologics

Most Recent Events

10 Oct 2022 Planned End Date changed from 21 Aug 2024 to 21 Jun 2023.
10 Oct 2022 Planned primary completion date changed from 21 May 2024 to 21 Dec 2022.
10 Oct 2022 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com